Clinical Evidence: REDEFINE Program# REDEFINE 1 (Without Type 2 Diabetes)# 3,417 adults randomized to CagriSema (n=2,108), semaglutide alone (n=302), cagrilintide alone (n=302), or placebo (n=705) for 68 weeks
Patients with lower baseline subcutaneous adiposity may experience more injection-site reactions regardless of location
Discussing realistic expectations and current evidence gaps with a qualified provider is essential before considering use
further suggest that semaglutide may impact the gut microbial community during treatment, and the basal microbiome may predict changes in HbA1c in semaglutide users (despite methodological limitations and the need for replication) (41)
After childbirth, many women notice loose skin, stubborn fat deposits, and weakened or separated abdominal muscles that leave them feeling unlike their pre-baby selves